AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03441542 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Data-assisted Case Navigation
Description: The researchers will develop a monthly task list for the patient navigator with patient by patient care cascade and treatment milestones that need to be accomplished per patient in the case group. The researchers will deliver the spreadsheet and the task list to the Grady Liver Clinic Director who will use it to direct and supervise the activities of the patient navigator.~Patient navigators will be responsible for reaching out to patients in only the intervention arm about their next step in the HCV care cascade.
Study NCT03441542 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients will be recruited into the study by the patient navigator, be provided information about HCV infection, and will be informed that treatment is freely available should they seek it. Patients will also be provided contact and address information for the treatment clinic.
Study NCT02918565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drinking Cognition Feedback (DCF)
Description: 12 weeks of interactive text messaging focused on providing feedback related only to pre-weekend drinking cognitions (plans, desire to get drunk).
Study NCT02918565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Risk Feedback (ARF)
Description: 12 weeks of interactive text messaging focused on providing feedback related only to post-weekend alcohol consumption (max drinks consumed on any occasion over the weekend).
Study NCT02918565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Goal Support (AGS)
Description: 12 weeks of interactive text messaging focused on providing adaptive goal support (based on running average of max drinks consumed).
Study NCT02918565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMBO
Description: 12 weeks of interactive text messaging incorporating features of DCF, ARF and AGS.
Study NCT02921724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TreC-Onco
Description: TreC-Onco is composed of two tools aimed at supporting patient self-care and health professional monitoring and intervention:~1. Mobile diary app. This is an Android app (for Android version 2.2 and higher) that allows patients to record parameters related to their health state (e.g. medications; blood pressure, weight, fever; side-effects or other symptoms) through a mobile device. Data are stored in a central database and are made available in real time to health professionals through a web dashboard on the TreC server or through a tablet app.~2. Web dashboard. Through this, oncologists can check patient data, monitoring their side-effects and adherence to prescriptions. The Dashboard is optimized for the Firefox browser in version 7 or higher.
Study NCT01168778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician Workshop
Description: Physicians that were assigned to the intervention group attended a 3.5 hour intervention workshop where they were trained in skills to communicate information about physical examination findings, treatment, and follow-up that will ultimately facilitate appropriate antibiotic prescribing and increase parent satisfaction with care.
Study NCT01788527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM
Description: Real Time Continuous Glucose Monitoring
Study NCT05057598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based participatory research on diet and lifestyle
Description: The intervention use a web site that contains a section to exchange information on recipes and on strategy to comply with the recommendations, and an agenda to inform on meetings, conferences, kitchen classes, walking groups, organised by the participant themselves. The investigators are developed specific recommendations for women with different characteristics. The investigators intend to improve the specificity of information with short questionnaires on portion size of relevant items using photographs or usual container in the kitchen and develop a health application for smartphone to facilitated a more efficient and timely exchange on information.~The participants will receive a free phone number for emergencies, active 2 hours a day for 5 days a week.
Study NCT03038867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine orally 60mg daily for 5 weeks, then taper to 30mg daily for 1 week
Study NCT03038867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally 2 tabs daily for 5 weeks, then taper to 1 tab daily for 1 week
Study NCT02619084 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STN DBS
Description: Bilateral STN DBS
Study NCT01852149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MPAS Implant
Description: The Mitralign System consists of a set of catheters that enable the physician to position and place sutures and anchors through the posterior (back) annulus of the mitral valve under the guidance of echocardiography and fluoroscopy. Once the anchored sutures are in place, the sutures are pulled together. When the valve leaflets are close together, the sutures are locked with at least one stainless steel lock. The Bident Translation Catheter allows implantation of two pairs of pledgets. Each pair of pledgets plicates the annulus and then the pledgets are locked together from the ventricular side with a lock.
Study NCT01057147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rebamipide 2% ophthalmic suspension
Description: Instill one drop in each eye four times daily for 12 weeks.
Study NCT01057147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo eye drops
Description: Instill one drop in each eye four times daily for 12 weeks.
Study NCT01208142 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care treatment
Description: weekly standardized physical therapy and daily wear of an AFO
Study NCT01208142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Flexion Dynasplint
Description: Weekly standardized physical therapy, daily wear of an AFO and nightly wear of the ankle flexion Dynasplint
Study NCT01724970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProSeal
Description: Patients will be ventilated with PLMA
Study NCT01724970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supreme LMA
Description: Patients will be ventilated with SLMA
Study NCT02861586 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-CHIK low dose
Description: recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection, 5xE4 (± 0.5 log) TCID50/dose
Study NCT02861586 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-CHIK high dose
Description: recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection; 5xE5 (± 0.5 log) TCID50/dose
Study NCT02861586 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix®
Description: lyophilized mixed preparation containing the attenuated Schwarz measles virus strain, the RIT 4385 strain of mumps virus (derived from the Jeryl Lynn strain) and the Wistar RA 27/3 rubella virus strain. Powder and solvent for suspension for injection
Study NCT01019876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Study NCT01019876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Study NCT01019876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT01019876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Study NCT01019876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Study NCT01019876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit Anti-thymocyte Globulin
Study NCT01019876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Horse Anti-thymocyte Globulin
Study NCT03298451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous infusion).
Study NCT03298451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab (Regimen 1)
Description: Tremelimumab IV (intravenous infusion).
Study NCT02786498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Study NCT02861586 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Priorix®
Description: lyophilized mixed preparation containing the attenuated Schwarz measles virus strain, the RIT 4385 strain of mumps virus (derived from the Jeryl Lynn strain) and the Wistar RA 27/3 rubella virus strain. Powder and solvent for suspension for injection
Study NCT04538534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicardipine
Description: To compare the association of nicardipine and isosorbide dinitrate vs isosorbide dinitrate alone on the rate of occurrence of radial artery spasm
Study NCT05194813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aqua alvim CM, neodent implant (Test)
Description: Acqua, Hydrophilic sandblasted, and acid-etched dental implants
Study NCT05194813 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neoporous alvim CM, neodent implant (Control)
Description: Neoporous, Hydrophilic sandblasted, and acid-etched dental implants
Study NCT04036773 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable deliveries
Description: Weekly home deliveries of approximately 15 pounds of fresh fruits \& vegetables
Study NCT03298451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab (Regimen 2)
Description: Tremelimumab IV (intravenous infusion).
Study NCT02861586 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: physiological saline solution
Description: sterile physiological saline solution 0.9% used as placebo
Study NCT03298451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib, as per standard of care
Study NCT03298451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (Regimen 1)
Description: Durvalumab IV (intravenous infusion).
Study NCT03298451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (Regimen 2)
Description: Durvalumab IV (intravenous infusion).
Study NCT03860857 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Amyloid PET scan
Description: Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18
Study NCT02786498 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02786498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03860857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tau PET scan using MK-6240
Description: Tau Positron Emission Tomography scan using radio tracer MK-6240
Study NCT04137263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DOSE formulation
Description: over-the-counter topical
Study NCT05261113 — intervention group
Intervention type: PROCEDURE
Intervention: CE-IOUS
Description: Use of contrast-enhanced intraoperative ultrasound during liver surgery
Study NCT03500770 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulator
Description: The tDCS device to be used will be an investigational, battery powered, custom-made stimulator able to deliver a biphasic alternate current. Active stimulation consists of 10 active tDCS sessions with current intensity fixed at 2mA for 20 minutes. It has been safely used in several other research studies. The side effects profile for this type of stimulation include tingling/itching at the site of stimulation, skin irritation/redness at the site of stimulation, headache or dizziness.
Study NCT01147120 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Description: Progressive Muscle Relaxation (PMR) will be recorded on PDAs integrated with EMA software and offered to patients who will be instructed in the techniques and PDA use by study coordinators. They will be instructed to practice 25 minutes/day the first two weeks, 35 minutes/day weeks 3 and 4, and 45 minutes/day weeks 5 through 12. These time periods (25/35/45 minute) were selected to allow a more gradual acclimation to PMR.
Study NCT01147120 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Massage Therapy (CMT)
Description: PCPs will have the opportunity to refer patients with CLBP to local Licensed Massage Therapists (LMTs) to receive up to 10 clinical massage sessions over a 12-week period. CMT will be provided at no cost to the patients. At their first two sessions, the LMT will evaluate the patient and, with the patient, estimate the number of sessions and determine treatment goals. Based on previous literature, 10 sessions are anticipated over an average 12-week period. However, treatment will vary depending on assessment and progress. At the end of the treatment period, the patients will receive a list of all participating LMTs to facilitate patients' continued or future participation in massage therapy.
Study NCT01100684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asimadoline
Description: 0.5 mg Asimadoline BID
Study NCT02861586 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: physiological saline solution
Description: sterile physiological saline solution 0.9% used as placebo
Study NCT01100684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03414164 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: procyanidine
Description: natural antioxidants
Study NCT01174706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information prescriptions
Description: One arm will receive usual care at discharge. The other three arms will receive practical assistance and/or an information prescription which will consist of written information from Medline Plus and access to a clinical informationist if subject has additional information needs.
Study NCT03860857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurocognitive testing
Description: A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities.
Study NCT01050582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: As per local prescribing practices
Study NCT01050582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other atypical antipsychotic drugs
Description: As per local prescribing practices
Study NCT04353713 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 40% Dextrose Gel
Description: Prophylactic administration of 40% dextrose gel via buccal mucosa to prevent newborn hypoglycemia
Study NCT03860857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study.
Study NCT01655992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: 2500mg／m2／day divided into twice two weeks on one week off
Study NCT01655992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1 generic
Description: 40mg／m2 bid four weeks on two weeks off
Study NCT03279172 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: direct laryngoscope
Description: procedure entubatıon
Study NCT03279172 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: videolaryngoscope
Study NCT04353713 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 2% carboxymethylcellulose gel
Description: placebo
Study NCT01826513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard AutoSet algorithm
Description: An AutoSet device with a standard algorithm developed for sleep breathing parameters that are specific to a particular gender.
Study NCT01826513 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard AutoSet algorithm
Description: An AutoSet device with a standard algorithm developed for sleep breathing parameters that are specific to a particular gender.
Study NCT01826513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified AutoSet algorithm
Description: An AutoSet device with an algorithm developed for sleep breathing parameters specific to females.
Study NCT01826513 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified AutoSet algorithm
Description: An AutoSet device with an algorithm developed for sleep breathing parameters specific to females.
Study NCT04593615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG near-infrared imaging
Description: Indocyanine green tracer is used to guide laparoscopic D2 lymph node dissection for gastric cancer
Study NCT04593615 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ICG near-infrared imaging
Description: Indocyanine green tracer is used to guide laparoscopic D2 lymph node dissection for gastric cancer
Study NCT02142803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT02913443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7051790
Description: RO7051790 will be given orally. Treatment will be continued until disease progression/treatment failure, unacceptable toxicity, or study discontinuation.
Study NCT00952835 — intervention group
Intervention type: OTHER
Intervention: regular treatment
Description: regular treatment
Study NCT02142803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02142803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02142803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO
Study NCT00297752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceriumnitrate silversulfadiazine (flammacerium)
Description: treatment of patients with facial burns with CE-SSD
Study NCT00297752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: silversulfadiazine (flammazine)
Description: treatment of patients with facial burns with SSD
Study NCT00168025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoglobulins Intravenous (Human)
Study NCT05530135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: Exercise program
Study NCT05530135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioural therapy
Description: Cognitive behavioural therapy
Study NCT05530135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard clinical care
Description: Standard clinical care
Study NCT05530135 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard clinical care
Description: Standard clinical care
Study NCT03258983 — intervention group
Intervention type: OTHER
Intervention: Alpha-linolenic acid
Description: Exposure to dietary intake of alpha-linolenic acid (ALA) will be assessed using a detailed food frequency questionaire filled in by participants included in the Diet, Cancer and Health cohort at baseline. Exposure to adipose tissue content of ALA will be determined by gas chromatography in all incident cases and in subcohort of 3500 participants randomly drawn from the total cohort.
Study NCT01951105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Take one 250mg naproxen tablet three times a day for 12 weeks.
Study NCT01951105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen
Description: Take one 250mg naproxen tablet three times a day for 12 weeks.
Study NCT01951105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbidopa/Levodopa
Description: 12.5mg/50mg Carbidopa/Levodopa, administered orally as capsules, will be titrated up to TID over one week and then continued at that level for 4 weeks. If at the end of this initial 4 week period the participant has responded, the subject will be maintained on that dose for the duration of the treatment period (12 weeks total). If there has not been a response, the dose will be increased to 25mg/100mg Carbidopa/Levodopa TID for the following 4 weeks at which time the pain status will be re-evaluated. If a response has occurred, that dose will be maintained in a blinded manner for the following 4 weeks of treatment; if not, further dose-titration will occur to 50mg/200mg Carbidopa/Levodopa TID for the final 4 weeks. If a subject experiences an AE at higher doses, then the subject will be given the next lower dose that s/he was able to tolerate and then be maintained on that dose for the remainder of the 12 week dosing period.
Study NCT01951105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take two placebo capsules three times a day for 12 weeks.
Study NCT03234842 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Therapy
Description: 59.4 Gy (RBE) in 1.8 Gy per fraction plus weekly chemotherapy at standard doses
Study NCT03234842 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon Radiation Therapy
Description: 59.4 Gy (RBE) in 1.8 Gy per fraction plus weekly chemotherapy at standard doses
Study NCT03234842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Concurrent weekly chemotherapy at standard doses